Q4 EPS Estimate for Dynavax Technologies Lifted by Analyst

Dynavax Technologies Co. (NASDAQ:DVAX) – Investment analysts at William Blair lifted their Q4 2024 earnings estimates for shares of Dynavax Technologies in a research report issued on Monday, January 13th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings per share of $0.02 for the quarter, up from their previous forecast of $0.01. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.19 per share. William Blair also issued estimates for Dynavax Technologies’ FY2026 earnings at $0.48 EPS.

Several other analysts also recently weighed in on DVAX. StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday. HC Wainwright upped their price target on Dynavax Technologies from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday.

Dynavax Technologies Stock Performance

Shares of NASDAQ:DVAX opened at $12.48 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The stock’s 50-day moving average is $12.77 and its 200-day moving average is $11.66. The company has a market cap of $1.64 billion, a P/E ratio of 96.01 and a beta of 1.34. Dynavax Technologies has a 52-week low of $9.74 and a 52-week high of $14.41.

Hedge Funds Weigh In On Dynavax Technologies

Large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its position in shares of Dynavax Technologies by 175.5% during the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 1,685 shares during the period. US Bancorp DE increased its holdings in Dynavax Technologies by 291.4% in the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,034 shares during the period. Capital Performance Advisors LLP bought a new position in shares of Dynavax Technologies during the 3rd quarter worth about $45,000. Nisa Investment Advisors LLC boosted its position in shares of Dynavax Technologies by 44.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 1,679 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new stake in Dynavax Technologies in the third quarter valued at about $89,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.